The vascular endothelial growth factors (VEGFs) are major angiogenic regulators and are involved in several aspects of endothelial cell physiology 1 . However, the detailed role of VEGF-B in blood vessel function has remained unclear 2, 3 . Here we show that VEGF-B has an unexpected role in endothelial targeting of lipids to peripheral tissues. Dietary lipids present in circulation have to be transported through the vascular endothelium to be metabolized by tissue cells, a mechanism that is poorly understood 4 . Bioinformatic analysis showed that Vegfb was tightly co-expressed with nuclear-encoded mitochondrial genes across a large variety of physiological conditions in mice, pointing to a role for VEGF-B in metabolism. VEGF-B specifically controlled endothelial uptake of fatty acids via transcriptional regulation of vascular fatty acid transport proteins. As a consequence, Vegfb 2/2 mice showed less uptake and accumulation of lipids in muscle, heart and brown adipose tissue, and instead shunted lipids to white adipose tissue. This regulation was mediated by VEGF receptor 1 and neuropilin 1 expressed by the endothelium. The co-expression of VEGF-B and mitochondrial proteins introduces a novel regulatory mechanism, whereby endothelial lipid uptake and mitochondrial lipid use are tightly coordinated. The involvement of VEGF-B in lipid uptake may open up the possibility for novel strategies to modulate pathological lipid accumulation in diabetes, obesity and cardiovascular diseases.
The vascular endothelial VEGFs, comprising VEGF-A, placental growth factor (PLGF) and VEGF-B, signal via the endothelial receptors VEGF receptor 1 (VEGFR1) and VEGFR2, and are major regulators of blood vessel physiology 1, [5] [6] [7] . VEGF-A is required for vasculogenesis and angiogenesis, and is induced by hypoxia and nutrient deprivation [8] [9] [10] . PLGF is involved in pathological angiogenesis 11 , whereas VEGF-B is poorly angiogenic in most tissues except heart 12, 13 . This is surprising as both PLGF and VEGF-B signal through the same receptors, VEGFR1 (refs 5, 6 ) and neuropilin 1 (NRP1) 14, 15 . Mice lacking VEGF-B (Vegfb 2/2 mice) are healthy and fertile 2, 3 , whereas cardiac overexpression of VEGF-B causes cardiomyocyte hypertrophy and ceramide accumulation 16 . The detailed biological role of VEGF-B has, however, remained obscure.
We clustered publicly available microarray data to identify genes that are co-expressed with Vegfb, and thereby establish links to known signalling pathways or metabolic networks. Unexpectedly, Vegfb expression was tightly co-regulated (r 5 0.90) with a large cluster of nuclear genes coding for mitochondrial proteins (Fig. 1a and Supplementary Table 1) . A second analysis, using the SymAtlas mouse data set 17 , confirmed the correlated expression of Vegfb and mitochondrial genes (Fig. 1b) . Identical analyses of Plgf (also called Pgf) and Vegfa demonstrated considerably lower correlations with the mitochondrial cluster (r # 0.30, Supplementary Fig. 1 ), and their correlated genes were not mitochondrial (Fig. 1b) . Using quantitative polymerase chain reaction (qPCR), Vegfb was found to have a similar expression pattern as two mitochondrial markers-NADH dehydrogenase 1 a subcomplex 5 (Ndufa5) and cytochrome c somatic (Cycs)-across several mouse tissues ( Fig. 1c and Supplementary  Fig. 2 ) and in response to different nutritional changes (Fig. 1d) . However, the expression patterns of Plgf and Vegfa differed (Fig. 1c) .
Analysis of Vegfb
2/2 mice demonstrated that VEGF-B does not regulate the expression of the mitochondrial genes or influence mitochondrial copy number ( Supplementary Fig. 3 ). Instead, the co-expression of Vegfb with the genes in the mitochondrial cluster is probably due to transcriptional regulation by oestrogen-related receptor a (ERRa) and its co-activator PPAR-c co-activator 1a (PGC-1a) (X.W. and U.E., unpublished data), which are major modulators of mitochondrial function 18 . Taken together, these results pointed to a unique role for VEGF-B in energy metabolism.
VEGF-B is highly expressed in heart, oxidative skeletal muscle and brown adipose tissue (BAT; Fig. 1c ), all of which are tissues enriched in mitochondria and which mainly use fatty acids as energy source. We hypothesized that VEGF-B affects energy metabolism by instructing endothelial cells to take up long-chain fatty acids (LCFAs) from the circulation, for further transfer to the surrounding tissue for mitochondrial use (Fig. 1e) . We therefore analysed whether VEGF-B stimulation of endothelial cell lines, or primary endothelial cells, could induce the expression of known fatty acid handling proteins, including the fatty acid transport proteins (FATPs), the fatty acid binding proteins, or the scavenger receptor CD36 (ref. 4) . Treatment of endothelial cells with either of the VEGF-B splice isoforms 19 , VEGF-B 167 or VEGF-B 186 , increased both messenger RNA and protein expression of several FATPs, with the diffusible VEGF-B 186 isoform being more efficient (Fig. 2a, b and Supplementary Figs 4 and 5 ). Other VEGFR1 ligands had no effect (Fig. 2c) , and VEGF-B treatment did not alter the expression of CD36 or fatty acid binding proteins (data not shown). Moreover, VEGF-B did not induce FATP expression in NIH-3T3 fibroblasts ( Supplementary Fig. 6 ), pointing to an endothelial-specific effect. Pre-incubation of cultured endothelial cells with neutralizing antibodies against VEGFR1 and/or NRP1 showed that both receptors were essential for VEGF-B-mediated signal transduction, whereas a neutralizing VEGFR2 antibody had no effect (Fig. 2d) . Experiments using pharmacological kinase inhibitors indicated that VEGF-B controlled FATP transcription through a phosphatidylinositol-3-OH kinase (PI(3)K)-dependent pathway (Supplementary Fig. 7) . Notably, a tenfold molar excess of PLGF did not prevent VEGF-B 186 -induced expression of the FATPs (Fig. 2e) . This indicates that VEGF-B and PLGF signal through different receptor binding sites and/or structural variants, or alternatively, act by recruiting distinct co-receptors to the signalling complex, thereby allowing ligand-specific signalling in both angiogenesis and regulation of the FATPs.
To analyse whether VEGF-B is able to induce FATP expression in vivo, adenoviruses (Ad) encoding different VEGFs, or LacZ, were directly injected into mouse hearts. Notably, a 50% increase in Fatp3 (also called Slc27a3) and Fatp4 (Slc27a4) mRNA expression was detected only in AdVEGF-B transduced hearts (Fig. 2f and Supplementary Fig. 8 ). In Vegfb 2/2 mouse tissues, mRNA and protein levels of several FATPs were conversely reduced (Figs 2g, h and Supplementary Fig. 9 ). The cardiac expression of FATPs was also downregulated in mice lacking the tyrosine kinase domain of VEGFR1 (Flt1-TK 2/2 mice 20 ) , showing that VEGFR1 signalling is essential for VEGF-B to regulate the FATPs in vivo (Fig. 2i) fl/fl mice (Nrp1-EC-WT mice) (Fig. 2j) . We conclude that the FATPs are downstream targets of VEGF-B, and that VEGF-B regulates FATP expression in an endothelial-cell-mediated fashion via VEGFR1 and NRP1 signalling.
It has not previously been established whether the endothelium expresses FATPs in vivo 22 . To confirm that VEGF-B regulates transcription of vascular FATPs, we isolated endothelial cells from heart, BAT and lung of wild-type and Vegfb 2/2 mice ( Supplementary Fig. 10 ). In wild-type heart and BAT, Fatp3 mRNA was detected in the endothelial cell fraction, Fatp1 in the non-endothelial-cell fraction, whereas Fatp4 was expressed in both fractions ( Fig. 3a and Supplementary Fig. 11 ). When comparing the expression of the FATPs in cell fractions isolated from animals of both genotypes, we observed that Fatp3 and Fatp4 were significantly downregulated in the Vegfb 2/2 endothelial cells from heart and BAT ( Fig. 3b and Supplementary Fig. 11 ), whereas there was no expressional change in any of the non-endothelial-cell fractions. Furthermore, the vascular response to VEGF-B was tissuespecific, as endothelial Fatp3 expression was unchanged between genotypes in lung, an organ with low VEGF-B content ( Fig. 1c and Supplementary Fig. 11 ). The vascular expression of FATP3 and FATP4 in heart and skeletal muscle was confirmed by immunostaining ( Fig. 3c and Supplementary Fig. 12 ). Taken together, these data showed that FATP3 is an endothelial-specific FATP, and that VEGF-B specifically controls the expression of the vascular FATPs, Fatp3 and Fatp4, in endothelial cells in several lipid-metabolizing peripheral tissues.
The mechanism by which the FATPs accumulate LCFAs in cells also remains controversial 22, 23 . We transfected cultured endothelial cells with expression plasmids encoding FATP3, FATP4, or mock control, and quantified the cellular uptake of a 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid-labelled saturated LCFA analogue (BODIPY-FA). FATP3 transfection led to increased BODIPY-FA uptake ( Fig. 3d and Supplementary Fig. 13 ). FATP4 was more potent in inducing BODIPY-FA uptake, whereas the co-expression of both FATPs resulted in the highest cellular lipid accumulation, indicating a synergistic effect of the two FATPs. Adding a 103 molar excess of unlabelled oleic acid to the uptake assay abolished BODIPY-FA uptake, demonstrating a saturable uptake mechanism (Supplementary Fig. 13 ). Treating cultured endothelial cells with VEGF-B 186 significantly induced cellular LCFA uptake (Fig. 3e) . Conversely, silencing Fatp3 or Fatp4 expression by short interfering RNA (siRNA) transfection reduced the capacity of the cells to accumulate BODIPY-FA, and blunted the effect of VEGF-B treatment ( Fig. 3e and Supplementary Fig. 14) . Thus, VEGF-B induced endothelial LCFA uptake in a FATP-dependent manner. VEGF-B treatment of HL-1 cells, a cultured cardiomyocyte cell line, did not induce LCFA uptake, further supporting an endothelialcell-specific effect of VEGF-B (data not shown).
To study LCFA transport across the endothelium, we cultured endothelial cells on cell culture insert membranes, creating two liquid compartments separated by a tight monolayer of cells, mimicking the endothelium of blood vessels. VEGF-B treatment significantly increased trans-endothelial transfer of 14 C-labelled oleic acid ( 14 C-OA) from the upper to the basal liquid compartment, without affecting endothelial permeability 24 ( Fig. 3f and Supplementary Fig. 15 ), supporting the hypothesis that LCFAs are transported across the endothelial monolayer via a protein-mediated, intracellular pathway abolished the transport (Fig. 3g) . We conclude that VEGF-B has a unique role in the regulation of trans-endothelial LCFA transport.
To address whether Vegfb 2/2 mice displayed defects in LCFA uptake to peripheral organs, mice were given 14 C-OA by oral gavage, and uptake of the tracer was measured in plasma and in peripheral organs after extensive perfusion. Plasma 14 C levels were transiently higher in Vegfb 2/2 mice compared with wild-type controls (Fig. 4a) . Furthermore, the data showed that Vegfb 2/2 mice have normal intestinal lipid adsorption as the initial raise in radioactivity was identical between the two genotypes. Animals of both genotypes also expressed equal levels of Cd36 and Fatp4, the major intestinal lipid-handling proteins, in their small intestines 25, 26 ( Supplementary Fig. 16 ). Basal levels of plasma triglycerides and non-esterified fatty acids were also normal in the Vegfb 2/2 mice ( Supplementary Fig. 17 ). Two hours after oral gavage significantly less 14 C-LCFAs had accumulated in Vegfb 2/2 heart, muscle and BAT as compared with wildtype organs (Fig. 4b ). The differences were detectable already at 30 min after gavage (data not shown) and persisted for 24 h. We found that 14 C-OA instead accumulated in Vegfb 2/2 white adipose tissue (WAT) pads after 24 h ( Fig. 4c and Supplementary Fig. 18 ). Accordingly, Vegfb 2/2 mice gained more weight with age, and 16-18-week-old Vegfb 2/2 mice were 15% heavier then matched wild-type mice (Vegfb
, 29.9 6 1.5 g; wild type, 26.1 6 1.0 g, n 5 11-15, P , 0.001). Dissected Vegfb 2/2 fat pads were also 60-90% larger ( Supplementary Fig. 19 ), and using magnetic resonance imaging (MRI) we demonstrated that Vegfb 2/2 animals have higher body fat mass ( Fig. 4d and Supplementary Fig. 19 ). These data showed that Vegfb 2/2 mice have lower lipid uptake into peripheral organs, and instead shunt excess lipids to WAT. phenotypes ( Supplementary Fig. 22 ). Furthermore, we found less ORO staining in Vegfb 2/2 livers, ruling out hepatic accumulation of excess lipids (data not shown). Finally, we confirmed, biochemically and by transcriptional analyses of key genes, that VEGF-B does not regulate b-oxidation (Supplementary Table 2 and Supplementary  Fig. 23 ).
Reduced intramyocellular lipid accumulation has been proposed to enhance glucose use and insulin sensitivity of myocytes 27, 28 , and we therefore analysed the uptake of Fig. 4i and Supplementary Fig. 24 ). The expression level of Glut4, mice (j) compared to control mice. NS, not significant. *P , 0.05, **P , 0.01, ***P , 0.001.
the major glucose transporter in heart and skeletal muscle, was also increased in Vegfb 2/2 hearts compared to wild-type controls (Supplementary Table 2 ). Taken together, the molecular machinery for accumulation of [ 18 F]FDG from the blood is more active in the Vegfb 2/2 hearts as compared to controls, indicating a compensatory increase in carbohydrate use for energy production, and possibly a metabolic shift.
We show here that VEGF-B has a unique role in controlling endothelial LCFA transport. As a consequence, Vegfb 2/2 and Nrp1-EC 2/2 animals have a defective fatty acid uptake to peripheral tissues, and a reduced accumulation of intramyocellular lipids. Our results indicate that VEGF-B is part of a novel metabolic circuit (Fig. 1e) , which has a critical role in coordinating endothelial-cellmediated LCFA uptake with the energy demand of the surrounding tissue. We propose that by co-expressing Vegfb and mitochondrial genes, parenchymal cells ensure that endothelial uptake of LCFAs from the circulation is matched to the oxidative capacity of the tissue, thereby avoiding intracellular accumulation of excess lipids and subsequent lipotoxicity 29 . The finding that a member of the VEGF family, VEGF-B, has a unique role in fatty acid accumulation is surprising, and may open up the possibility for novel strategies to modulate pathological lipid accumulation in diabetes, obesity and cardiovascular diseases.
METHODS SUMMARY
Bioinformatics. Microarray expression data from 44 data sets, all generated using the Affymetrix U74A platform, were downloaded from the GEO database 30 . Arrays were intensity normalized and merged into one 708 array data set. A hierarchical clustering procedure (average group linkage, Pearson correlation, threshold r . 0.8) was applied to identify groups of co-expressed genes. hearts. Inset, representative PET image of hearts (arrowhead) after 60 min (n 5 3-4). Scale bar, 50 mm. *P , 0.05, **P , 0.01, ***P , 0.001.
Statistics. In all figures data are presented as mean 6 s.e.m. from pooled data of 2-5 independent experiments. P-values were calculated with one-way analysis of variance (ANOVA) and two-tailed independent Student's t-tests, and P , 0.05 was considered significant. 
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METHODS
Bioinformatics (continued). The GNF SymAtlas database 17 was used to find all mouse transcripts (cutoff value $ 0.80) correlating with the expression of mouse Vegfb, Pgf (termed Plgf in the manuscript for clarity) or Vegfa transcripts. To classify the correlated transcripts according to their subcellular localization, GeneOntology component information from NCBI Entrez Gene was used. Mice (continued). Male mice were used throughout the study. To study the effect of nutritional challenges on Vegfb expression, wild-type and Vegfb 2/2 mice were kept on standard chow, fasted overnight (18 h), or fed a high-fat diet (D12451, Research Diets) for 5 weeks before sacrifice. For all other studies the mice were kept on standard chow and were non-fasted before sacrifice.
EC-SCL-Cre-ER T positive Nrp1 fl/fl (Nrp1-EC
2/2
) and EC-SCL-Cre-ER T negative Nrp1 fl/fl (Nrp1-EC-WT) mice (gift from D. Cheresh) were injected intraperitoneally for 2 weeks 21 every other day with 100 ml of 20 mg ml 21 tamoxifen (Sigma) dissolved in corn oil (Sigma), after which the mice were directly killed, or intravenously injected with adenoviruses as described below, and subsequently killed 5 days later. Quantitative RT-PCR (qPCR) analysis. Tissues from 8-16 week male mice were dissected, frozen in liquid nitrogen and kept at 280 uC. Oxidative muscle (M. soleus) was used in all studies, apart from data in Fig. 1c where glycolytic muscle (the quadriceps femoris muscle group) was also analysed. Epididymal WAT was used in all studies except when otherwise indicated. BAT was dissected from the interscapulal depot of the mice. Whole tissue RNA was isolated with TRIzol reagent (Invitrogen) and QIAGEN RNeasy (Qiagen) according to the manufacturers' instructions. For expression studies in cell cultures (see below), cultured cells were washed with PBS, lysed with RLT buffer (Qiagen) and passed through a shredder column (Qiagen) and RNA was isolated using RNAeasy (Qiagen).
Total RNA (1 mg) was reverse transcribed according to the manufacturer's instructions (iScript cDNA synthesis kit, Bio-Rad). qPCR was performed using Platinum SYBR green SuperMix (Invitrogen) and 25 ng cDNA per reaction. Primer sequences are listed in Supplementary Table 3 . Expression levels were normalized to the expression of L19 and/or 2-microglobulin. Cell culture. Mouse bEnd3 cells (ATCC) were cultured in high glucose DMEM (Gibco) supplemented with 10% FCS, 3.7 g l 21 NaHCO 3 , 2 mM glutamine, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin according to the manufacturer's instructions. Mouse Mile Sven-1 cells (MS-1, gift from T. Vincent), the telomerase-immortalized human dermal microvascular endothelium cell line (TIME), human dermal microvascular endothelial cells (HDMECs) and human umbilical vein endothelial cells (HUVECs) were maintained in endothelial cell basal medium MV2 (Promo Cell) supplemented with MV2 Supplement pack growth factors (Promo Cell), 100 U ml 21 penicillin and 100 mg ml 21 streptomycin according to the manufacturer's instructions. mVEGF-B 186 , mVEGF-B 167 , mPLGF2, mVEGF-A 164 , soluble hVEGFR1 and neutralizing antibodies against mVEGFR1, mVEGFR2 and rat NRP1 were purchased from R&D Systems. The anti-VEGF-B monoclonal antibody 2H10 31 was a gift from A. Nash. For treatment of endothelial cells with VEGF-B, PLGF, VEGF-A or mock treatment, cells were starved in growth medium containing 0.5% FCS for 4-12 h followed by addition of 100 ng ml 21 of the growth factors, or 1 mg ml 21 of sVEGFR1 or anti-VEGF-B monoclonal antibody, or only new medium for mock treatment, and further incubated for 20 h. In another set of experiments, cells were preincubated for 2 h with neutralizing antibodies against VEGFR1 (4 mg ml 21 ), VEGFR2 (0.3 mg ml 21 ), or NRP1 (1 mg ml 21 ), and VEGF-B 186 was then added to the medium as described above. As a control, cells were also treated with antibodies alone, which showed not to have an effect on FATP expression (data not shown). For competition experiments, 1 mg ml 21 of mPLGF was added together with 100 ng ml 21 of VEGF-B 186 . The involvement of protein kinases in downstream signalling of VEGF-B was analysed using pharmalogical inhibitors. For these experiments, cells were pre-incubated with 0.1 mg ml 21 LY294002 (PI(3)K inhibitor), 10 mM PD98059 (MEK1 inhibitor), or 10 mM U0126 (MEK1 and MEK2 inhibitor) for 2 h before addition of 100 ng ml 21 VEGF-B 186 to the medium. Total RNA fractions or protein lysates (see below) were generated as described before. All experiments were performed in triplicates, and were repeated at least three times.
Immunoblotting. For protein analysis of stimulated MS-1 and bEnd3 cells (see above), cells were washed in PBS and incubated in cell lysis buffer (20 mM TrisHCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholic acid and 0.5% Triton-X100) on ice for 10 min. Cells were detached by scraping, and centrifuged for 10 min at 10,000g at 4 uC. For immunoprecipitation, 2 mg of affinity-purified anti-mFATP4 antibody (Santa Cruz) was added to the suspension and incubated end-over-end for 90 min at 4 uC. Protein-A beads were added, and the mixture was further incubated for 30 min. Precipitated proteins were subjected to SDS-PAGE and immunoblotting as described below.
Hearts from 8-12-week-old male wild-type and Vegfb 2/2 mice were frozen in liquid nitrogen and kept at 280 uC. Frozen tissues were homogenized in tissue lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl 2 , 1% Triton-X100, 0,5% deoxycholic acid and 0.1% SDS) supplemented with Complete Protease Inhibitor Cocktail (Roche). Tissue lysates were incubated on ice for 30 min followed by centrifugation at 16,000g at 4 uC for 20 min where after the lysates were subjected to SDS-PAGE on NuPage 12% Bis-Tris gels (Invitrogen) under reducing conditions. Separated proteins were blotted onto filters using the iBlot system (Invitrogen). FATP3 was detected with a rabbit antiserum raised against a peptide corresponding to amino acid residues 24-42 of mFATP3, whereas an affinity purified polyclonal rabbit anti-mFATP4 antibody (Santa Cruz) and goat anti-mCD36 antibody (R&D Systems) were used to detect FATP4 and CD36, respectively. Blotting with goat polyclonal anti-mouse calnexin antibody (Santa Cruz) was used as loading control. Bound antibodies were detected with Enhanced Chemiluminescence Plus reagent (Amersham). Heart adenoviral transductions. 10-13-week-old male C57BL/6J mice were used. The mice were housed in standard housing conditions in The National Laboratory Animal Center of Kuopio University, and all animal procedures were carried out in accordance with the guidelines of the Experimental Animal Committee of Kuopio University. Adenoviral constructs encoding hVEGF-B 186 , hVEGF-A 165 , mPLGF2 or LacZ were used in this study. The human clinical grade first generation serotype 5 replication deficient (E1, partially E3 deleted) adenovirus stocks were produced in 293 cells as described 32 . Adenoviral constructs (6 to 17 ml of 1 3 10 12 viral particles per ml) were injected directly into the anterior wall of the left ventricle by ultrasound guidance. The injections were carried out as described 33 . Analgesic (carprofen 50 mg ml 21 , Rimadyl) was given after the injections. The mice were killed 6 days after injection by cervical dislocation. The hearts were perfused with PBS, the left ventricle was dissected and frozen in liquid nitrogen. RNA expression was further analysed as described above. Isolation of endothelial cells from mouse heart, BAT and lung. Male age-matched wild-type and Vefgb 2/2 mice were anaesthetized with avertin or hypnorm/ dormicum, and perfused with cold PBS. Organs were dissected, diced and incubated for 50 min at 37 uC under shaking (for hearts) or end-over-end turning (for BAT and lung) with EC buffer (HBSS (Invitrogen), 1% BSA, 25 mM HEPES and 5% cell dissociation buffer (GIBCO)) supplemented with 5 mg ml 21 collagenase A (Roche Diagnostics), 0.7 mg ml 21 hyaluronidase, and 100 U ml 21 DNase I (Invitrogen). The cell suspension was filtered two times through a 70 mm nylon mesh (Falcon) followed by two times filtrations through a 40 mm nylon mesh. The meshes were washed with ice-cold EC-buffer supplemented with 100 U ml 21 DNase I, and the suspension was centrifuged at 200g for 10 min at 4 uC. The cell pellets were resuspended in 1 ml EC-buffer and incubated for 30 min at 4 uC with 50 ml Dynabeads Biotin Binder (Dynal), which had been pre-coated according to the manufacturer's instructions with 3 mg biotinylated anti-CD31 antibody (BD Biosciences, Pharingen). Endothelial cells bound to the beads were isolated using a magnetic particle collector, and the remaining cell suspension (non-endothelial cell fraction) was collected, centrifuged for 2 min at 200g, and the cell pellets were saved. Endothelial cell beads were washed ten times with EC-buffer and both endothelial cells and non-endothelial cells were lysed in RLT buffer (Qiagen) and passed through a Shredder column (Qiagen). RNA was isolated and reverse transcribed as described above, using 100-400 ng RNA per reaction. The purity of the isolated cell fractions (endothelial cell and non-endothelial cell) was analysed by conventional RT-PCR of marker genes (primer sequences in shown in Supplementary Table 3) using 5 ng of endothelial cell, or non-endothelial cell, cDNA per reaction. Tissue cDNA from whole heart in a 3-5 times excess was used as positive control. The relative expression levels of the FATPs in endothelial cell and non-endothelial cell fractions were determined by qPCR as described above. Immunohistochemistry. Heart, muscle and interscapular BAT from male agematched wild-type and Vegfb 2/2 mice were PFA perfused, dissected and postfixated in 4% PFA overnight, and subsequently processed for paraffin imbedding using standard procedures.
Immunolocalization of FATP3, FATP4 and slow-twitch myosin in heart and muscle was performed using the Elite ABC Vectastain and Vector M.O.M. Immunodetection kit (Vector laboratories) using a mouse anti-FATP3 monoclonal antibody (Abcam), an affinity-purified polyclonal rabbit anti-FATP4 antibody (Santa Cruz), and a mouse monoclonal antibody against type I (slow) skeletal myosin (GeneTex Inc.). Antigen retrieval was obtained by heating tissue slides in 0.01 M citrate buffer, pH 6.0, at 95 uC for 20 min followed by treatment with 0.25 mg ml 21 trypsin for 30 min at 37 uC. Negative controls were stained simultaneously using only the secondary antibodies. Sections were counterstained with haematoxylin and eosin and mounted with Sakura mounting medium before analysis by bright-field microscopy.
BAT sections were stained with haematoxylin and eosin and mounted with Sakura mounting medium before analysis by bright-field microscopy. For quantification of the amount of lipid vacuoles in haematoxylin-and-eosin-stained BAT sections, the number of pink pixels from the eosin staining in each frame was calculated using images imported into Adobe Photoshop, and subtracted from the total number of pixels in each frame, giving the amount of non-stained pixels. These quantifications were done on three fields per section from three independent experiments (n 5 7 mice per genotype). Cloning of hFATP3 and mFATP4 plasmids. The hFATP3-pOTB7 plasmid containing the entire, sequenced human FATP3 mRNA was purchased from GeneService. The EST clone mFATP4-pYX-Asc (IMAGp998O2014352Q1) was purchased from RZPD, Germany. Both cDNAs were cut out (EcoRI/XhoI for human FATP3; EcoRI/NotI for mouse Fatp4), the inserts were gel-purified using the DNA gel Extraction Kit (Genomics), and directly ligated into the expression vector pcDNA3.1 (Invitrogen). The plasmids were verified by sequencing. BODIPY uptake assay. Cells were seeded in 24-well plates and cultured as described above using growth medium containing 1% fatty acid free BSA (FF-BSA) and no FCS for the experiments. bEnd3 cells were transfected with hFATP3-pcDNA3.1, mFATP4-pcDNA3.1, with both plasmids simultaneously, or with empty vector (mock) using the Lipofectamine LTX transfection system together with Plus-reagent (both from Invitrogen) according to the manufacturer's instructions. In another set of experiments, to explore the VEGF-Bmediated effect on lipid uptake, cells were treated with VEGF-B 186 (300 ng ml 21 ) or anti-VEGF-B monoclonal antibody (2 mg ml 21 ) for 27 h in FF-BSA growth medium. Twenty seven hours after transfection, or after growth factor treatment, cells were washed with PBS-1% FF-BSA and incubated for 3 min in 37 uC with PBS, 1% FF-BSA, 20 mM C 1 -BODIPY-C 12 (#3823, Sigma). Cells were washed vigorously, fixed with 4% PFA for 10 min at room temperature (23 uC) , and analysed by inverted microscopy. For each experiment, three or more wells were photographed diagonally using a 203 objective and equal exposure times, and all frames (n . 10) were used for computer-assisted quantification of green fluorescent pixels using Photoshop. The experiments were repeated at least three times in triplicates. Targeting FATP expression with siRNAs. Dharmacon specific targeting Accell SMARTpool siRNA towards mouse Fatp3 (no. E-049600-00; target sequences UUCUCAGGCUCCAGGAAUC, CGGGUAUCUUUUGUAUAUG, CCCUUC UCCUUGAUUCGAU, CCUUUGGAUUUGGUUCGGA) and mouse Fatp4 (no. E-063631-00, target sequences GCUGUUUGCUUCAAUGGUA, GCUUU GACCUCAGGAUCUU, CUGUGAGUCUGUGUUGCUU, GGAGGAUACUU GGCGUCUU), as wells as a red-fluorescence control mouse siRNA kit (no. K-005000-R1-0Y, including red fluorescent non-targeting siRNA, non-labelled scrambled siRNA, and mouse Gapdh targeting siRNA, Dharmacon) were used for the assay. bEnd3 cells were seeded in 24-well plates and transfected with 1 nmol siRNA per well according to the manufacturer's instructions. Forty eight hours after transfection the transfection medium was exchanged for growth medium containing 1% FF-BSA and either VEGF-B 186 or anti-VEGF-B monoclonal antibody as described above, and the cells were additionally incubated for 24 h. Cells were assayed for BODIPY-FA uptake as described above, but they were not fixed. After microscopic analysis the cells were trypsinized, lysed in RLT lysis buffer (Qiagen), and RNA was extracted as described above. The experiment was repeated twice with a total of 6-10 wells analysed per siRNA transfection. In vitro lipid transport assay. bEnd3 cells were seeded with a density of 60,000 cells per well on 24-well cell culture inserts (0.4 mm pore size, Falcon). Cells were grown as described above. After treatment of the cells with VEGF-B 186 , mPLGF, VEGF-A, anti-VEGF-B monoclonal antibody, anti-NRP1 antibody, or sVEGFR1 for 30 h, 0.5 mCi well 21 of 14 C-inulin (Amersham), or 14 C-oleic acid (PerkinElmer) was added to the apical chamber, and the cells were further incubated for 4 h. To assess the non-saturable background transport, some parallel experiments were performed in the presence of a 103 molar excess (70 mg ml 21 ) sodium oleate (Sigma) together with the 14 C-oleic acid as described 34 . Background was found to be of similar level independent of VEGF-treatment (data not shown). For kinetic studies, 50 ml samples were collected from the lower compartment every 20 min during the 4 h 14 C-oleic acid incubation period, and replaced with 50 ml medium. After 4 h, the whole basal liquid compartment was collected, suspended in Emulsifier Safe Liquid Scintillation Cocktail (PerkinElmer), and total radioactivity was measured by liquid scintillation. All experiments were performed in quadruplicates, and repeated at least three times. Fatty acid uptake in vivo. 8-12-week-old wild-type and Vegfb 2/2 mice were given a bolus dose of 2 mCi of 14 C-OA (PerkinElmer) dissolved in olive oil by oral gavage. Blood samples were drawn from the tail vein at 15, 30, 60 and 120 min after gavage, plasma was extracted by centrifugation for 1 min at 16,000g, and solubilized 1:6 in NCS-II Tissue Solubilizer (Amersham). BCS-NA Counting Scintillant (Amersham) was added and total radioactivity was measured by liquid scintillation. For analysis of lipid uptake into organs, the mice were anaesthetized with avertin for 30 min, 2 h or 24 h after gavage, perfused with PBS, and organs were dissected. The organs were dissolved overnight at 50 uC in tissue solubilizer (1 ml per 100 mg tissue), neutralized with 30 ml ml 21 glacial acetic acid and BCS-NA Counting Scintillant was added. Total radioactivity was measured by liquid scintillation using a Tri-Carb 1600 TR Liquid Scintillatior (Packard). MRI. MRI of 16-18-week-old male wild-type and Vegfb 2/2 mice was preformed at the Centre for Mouse Physiology and Imaging Core Facility at Göteborg University, Sweden, essentially as previously described 35, 36 . For MRI, mice were anaesthetized and placed in the centre of a 7 Tesla MR system (Burker BioSpin). Eighteen axial and coronal spin-echo measurements per mouse (1 mm slice thickness with 3.5 mm slice distance) were obtained covering all regions of the body, and the measurements were subsequently repeated with fat suppression to eliminate fast-flow regions. MR images were post-processed using the ImageJ software, and body fat percentage was calculated from the axial images as total area of true fat, normalized to total mouse area.
To confirm the MRI results regarding fat mass, 16-18-week-old male mice were killed and four fat pads (eWAT, rWAT (both intra-abdominal), iWAT and scWAT (both subcutaneous)) were dissected and weighed. Oil red O staining. Heart, oxidative (M. soleus) muscle and liver from age and sex matched wild-type and Vegfb 2/2 mice were dissected, rinsed in PBS and imbedded in Tissue-Tek (Sakura). Cryo-sections (12 mm) were immersed for 5-15 min in oil red O working solution (2.5 g oil red O (Sigma-Aldrich), dissolved in 400 ml 99% isopropanol, further diluted 6:10 in H 2 O, and finally filtered through a 22 mm filter (Corning)). Sections were rinsed in H 2 O, counterstained with Mayer's haematoxylin (Histolab), immersed in a 1:5 dilution of saturated Li 2 CO 3 and rinsed 10 min under running tap water before they were mounted. Stained sections were examined by light-field microscopy and .5 randomly selected fields were photographed in each section. For quantification of lipid droplets the amount of red pixels in each frame was calculated using images imported into Adobe Photoshop. All experiments were repeated three times. Intravenous injections of adenoviruses. Age-matched 6-month-old male wildtype and Vegfb 2/2 mice, or 4-month-old Nrp1-EC-WT and Nrp1-EC 2/2 mice, were injected with 9 3 10 8 p.f.u. of either empty control virus (AdCMV, n 5 4 wild-type and n 5 5 Vegfb 2/2 mice, or n 5 4 Nrp1-EC-WT and n 5 3 Nrp1-EC 2/2 mice) or an adenovirus coding for hVEGF-B 186 (AdVEGF-B 186 , n 5 5 Vegfb 2/2 mice or n 5 4 Nrp1-EC-WT and n 5 3 Nrp1-EC 2/2 mice) through the tail vein. Five days later the mice were anaesthetized, blood was collected, and organs were harvested and snap frozen. Half of each mouse heart was sectioned and used for ORO staining as described above, and the other half was used for RNA extraction and qPCR analysis, also as described above. As a control, the occurrence of hVEGF-B protein in plasma of mice receiving AdhVEGF-B was confirmed using a modified version of a previously established ELISA 37 . ELISA plates were coated overnight at 4 uC with 2 mg ml 21 of anti-VEGF-B antibody MAB751 (R&D Systems) dissolved in 50 ml of 100 mM NaHCO 3 , and subsequently blocked 30 min at room temperature with 3% BSA. Human recombinant VEGF-B 186 (gift from A. Nash) was used as a standard. 50 ml of four times diluted plasma samples was added to the wells, incubated overnight at 4 uC, washed, and hVEGF-B was detected using an affinity-purified rabbit anti-VEGF-B immunoglobulin for 1 h at room temperature. Bound rabbit immunoglobulin was detected with 50 ml of 1:5,000 dilution of anti-rabbit-IgG for 1 h at room temperature. Bound conjugates were visualized using 50 ml pNPP substrate (Sigma) and absorbance was read at 405 nm after 2 h incubation at 37 uC. PET scan. Positron emission tomography (PET) was performed on a Focus120 MicroPET (CTI Concorde Microsystems). The PET data were processed with MicroPET manager and evaluated using the ASIPro VM software (CTI Concorde Microsystems). 8-12-week-old non-starved male wild-type and Vegfb 2/2 mice were anaesthetized with isoflurane (5% initially and 1.5% to maintain anaesthesia) and placed on the camera bed on a heating pad (37 uC) . Under these experimental conditions all [ 18 F]FDG will be taken up by heart, or excreted to the bladder. [ 18 F]FDG was obtained from batches used for clinical PET imaging, which had passed radiochemical and pharmacological analysis. Mice received tail vein intravenous injections of 2.8-7.6 MBq [
18 F]FDG in a volume of 150 to 200 ml. Two animals from each group were analysed in parallel. The 60 min PET data acquisition started at injection. At the end of the scan mice were killed and the hearts were dissected and measured in a dose calibrator (Capintec). All data were normalized by the specific dose at the time of injection for each mouse.
